Geode Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Geode Capital Management LLC boosted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,708,301 shares of the biopharmaceutical company's stock after acquiring an additional 22,128 shares during the quarter. Geode Capital Management LLC owned 1.61% of Intra-Cellular Therapies worth $125,029,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. M&T Bank Corp lifted its stake in Intra-Cellular Therapies by 36.3% in the third quarter. M&T Bank Corp now owns 6,163 shares of the biopharmaceutical company's stock worth $451,000 after purchasing an additional 1,642 shares during the last quarter. Barclays PLC boosted its holdings in Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after acquiring an additional 25,435 shares during the period. Pier Capital LLC grew its position in Intra-Cellular Therapies by 1.6% during the 3rd quarter. Pier Capital LLC now owns 65,560 shares of the biopharmaceutical company's stock worth $4,797,000 after acquiring an additional 1,056 shares during the last quarter. State Street Corp increased its stake in Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after purchasing an additional 56,664 shares during the period. Finally, Quarry LP increased its stake in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after buying an additional 1,300 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Stock Down 0.3 %

ITCI traded down $0.24 during midday trading on Wednesday, reaching $86.72. The company had a trading volume of 1,068,516 shares, compared to its average volume of 826,764. The business has a 50-day moving average of $83.01 and a two-hundred day moving average of $77.12. Intra-Cellular Therapies, Inc. has a 1 year low of $62.78 and a 1 year high of $93.45. The company has a market cap of $9.19 billion, a P/E ratio of -99.68 and a beta of 0.95.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million during the quarter, compared to analysts' expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company's revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.25) earnings per share. On average, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analyst Ratings Changes

ITCI has been the subject of a number of recent analyst reports. Piper Sandler upgraded Intra-Cellular Therapies from a "neutral" rating to an "overweight" rating and upped their target price for the company from $68.00 to $92.00 in a report on Friday, September 6th. JPMorgan Chase & Co. boosted their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a research report on Monday, November 4th. Cantor Fitzgerald restated an "overweight" rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Needham & Company LLC reissued a "buy" rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada lifted their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an "outperform" rating in a report on Friday, October 4th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies currently has an average rating of "Moderate Buy" and a consensus price target of $97.23.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sharon Mates sold 51,000 shares of the business's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The disclosure for this sale can be found here. 2.60% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.